<!DOCTYPE html>
<html lang="en">

<head>
  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, shrink-to-fit=no">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <title>Aflibercept intravítreo 8 mg - PULSAR</title>
  <link href="https://cdn.jsdelivr.net/npm/bootstrap@5.3.0/dist/css/bootstrap.min.css" rel="stylesheet">
  <script src="https://cdn.jsdelivr.net/npm/bootstrap@5.3.0/dist/js/bootstrap.bundle.min.js"></script>
  <link rel="stylesheet" href="assets/css/styles.css">
  <link rel="stylesheet" href="assets/fonts/fontawesome-all.min.css">
  <script src="https://ajax.googleapis.com/ajax/libs/jquery/3.7.0/jquery.min.js"></script>
  <script src="assets/js/javascript.js"></script>
</head>

<body>
  <div class="row">
    <h3 style="font-size: 28px; width: 100%; color: white; font-weight: bold; background: #00617f; padding-top: 10px; padding-bottom: 10px;padding-left: 25px;">Aflibercept intravítreo 8 mg - PULSAR</h3>
  </div>

    
  <div>
    <button type="button" class="btn btn-back" id="back_button" onclick="location.href='index.html';">IVT-AFL 8 mg Overview</button><br>

    <h4>
      PULSAR
    </h4>
    <div class="card">
      <ul class="nav nav-tabs" role="tablist">
        <li class="nav-item" role="presentation"><a class="nav-link active" id="summary_tab" data-bs-toggle="tab" data-bs-target="#summary" href="#summary" role="tab">Resumen</a>
        </li>
        <li class="nav-item" role="presentation"><a class="nav-link" id= "design_tab" data-bs-toggle="tab" data-bs-target="#design" href="#design" role="tab">Design</a>
        </li>
        <li class="nav-item" role="presentation"><a class="nav-link" id= "results_tab" role="tab" data-bs-toggle="tab" href="#results">Results</a>
        </li>
        <li class="nav-item" role="presentation"><a class="nav-link" id= "safety_tab" role="tab" data-bs-toggle="tab" href="#safety">Safety</a>
        </li>
        <li class="nav-item" role="presentation"><a class="nav-link" id = "reference_tab" role="tab" data-bs-toggle="tab" href="#reference">References</a>
        </li>
      </ul>
    </div>
  
    <div class="tab-content">
      <div id="summary" class="tab-pane show active" role="tabpanel">
        <div class="container-fluid">
          <h1>
            Resumen<sup>1-3</sup>
          </h1>
          <ul class="bullet">
            <li>
              <a href="https://www.clinicaltrials.gov/study/NCT04423718" target="_blank">PULSAR</a> es un estudio de fase III, en curso, aleatorizado y con doble enmascaramiento, para evaluar el perfil de eficacia y seguridad de una formulación de aflibercept intravítreo (AFL-IVT) de 8 mg en comparación con AFL-IVT de 2 mg en el tratamiento de la degeneración macular asociada a la edad (DMAE) neovascular.
            </li>
            <li>
              PULSAR es un estudio de 96 semanas de duración, con la opción de ampliar los intervalos de tratamiento hasta 24 semanas y con una ampliación opcional de 1 año, sin enmascaramiento, hasta la semana 156.
            </li>
            <br>
            <p style="margin-left: -25px; margin-bottom: 0px;"><b>Eficacia en la semana 48<sup>1</sup></b></p>
            <li>
              El 83% de los pacientes tratados con AFL-IVT 8 mg mantuvieron intervalos de administración prolongados de &ge;12 semanas.
            </li>
            <li>
              El cambio medio en la mejor agudeza visual corregida (MAVC) desde el inicio hasta la semana 48 fue de <span class="teal">6.7</span>, <span class="blue">6.2</span> y <span class="gray">7.6</span> letras ETDRS (Early Treatment Diabetic Retinopathy Study) en los grupos <span class="teal">8q12</span>, <span class="blue">8q16</span> y <span class="gray">2q8</span>, respectivamente.
            </li>
            <br>
            <p style="margin-left: -25px; margin-bottom: 0px;"><b>Eficacia en las semanas 60 y 96<sup>2</sup></b></p>
            <li>
              En general, la mejora anatómica observada con IVT-AFL de 8 mg se mantuvo a lo largo del tiempo en las semanas 60 y 96.            </li>
            <li>
              En las semanas 60 y 96, respectivamente, el 91% y el 89% de los pacientes que recibieron IVT-AFL de 8 mg cada 16 semanas alcanzaron intervalos de dosificación &ge;12 semanas y el 77% y el 78% alcanzaron intervalos &ge;16 semanas.</li>
            <br> 
            <p style="margin-left: -25px; margin-bottom: 0px;"><b>Seguridad<sup>1-3</sup></b></p>
            <li>
              El perfil de seguridad de IVT-AFL de 8 mg fue comparable al de AFL-IVT de 2 mg durante 96 semanas.</li>
          </ul>          
        </div><br><br>
      </div>
  
      <div id="design" class="tab-pane"  role="tabpanel">
        <div class="container-fluid">
          <h1>
            Design<sup>1,2</sup>
          </h1>
          <ul class="bullet">        
            <li>
              Treatment-naïve patients ≥50 years of age with active subfoveal CNV secondary to nAMD, ETDRS BCVA letter scores of 78 to 24 (Snellen equivalent 20/32 to 20/320), decreased BCVA due to nAMD, and IRF and/or SRF present on optical coherence tomography that affected the central subfield were enrolled.
            </li>
            <li>
              Patients were randomized 1:1:1 to receive IVT-AFL 8q12, 8q16, or 2q8 after 3 initial monthly injections. Dosing regimen modifications were permitted starting at Week 16 for the IVT-AFL 8 mg groups, based on prespecified criteria.
            </li>
            <li>
              The primary endpoint at Week 48 was mean change in BCVA (non-inferiority).
            </li>
          </ul>
          <div class="container-collapse">
            <a class="btn btn-collapse" data-bs-toggle="collapse" aria-expanded="false" aria-controls="collapse-1" href="#collapse-1" role="button">Click to Expand/Collapse <br> Dosing Regimens
            </a>
          </div>
  
            <div id="collapse-1" class="collapse">
              <h2>
                Treatment Groups and Dosing Regimens Through Week 60<sup style="top: -0em">2</sup>
              </h2>
              <div class="figure zoom">
                <img src="assets/img/dosing.PNG" 
                class="img-fluid">
            </div>
          </div>
        </div><br><br>
      </div> 
            
      <div id="results" class="tab-pane" role="tabpanel">
        <div class="container-fluid">
          <h1>
            Results
          </h1>
          <div class="accordion">
            <div class="accordion-item">
              <h2 class="accordion-header" id="heading 1">
                <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#collapse-2">
                 Patients
                </button>
              </h2>
              <div id="collapse-2" class="accordion-collapse collapse">
                <div class="accordion-body">
                  <div class="container-collapse">
                    <a class="btn btn-collapse-white" data-bs-toggle="collapse" aria-expanded="false" href="#collapse-3" role="button">Click to Expand/Collapse <br> Baseline Demographics
                    </a>
                  </div>
          
                  <div id="collapse-3" class="collapse">
                    <h2>
                      Baseline Demographics (FAS)<sup style="top: -0em">1</sup>
                    </h2>
                    <div class="figure-white">
                      <img src="assets/img/baseline.PNG"
                      class="img-fluid">
                    </div>
                  </div>

                  <br>
                  <p style="margin-left: 10px; margin-top: -10px; font-size: 20px;">
                    <span class="teal">335</span> patients were randomized to <span class="teal">8q12</span>, <span class="blue">338</span> to <span class="blue">8q16</span>, and <span class="gray">336</span> to <span class="gray">2q8</span>.<sup>1</sup>
                  </p>
                  <p style="margin-left: 10px; font-size: 20px; font-weight: bold;">
                    Week 48<sup>1</sup>
                  </p>
                  <ul class="bullet-collapse">
                    <li>
                      Completion rates were <span class="teal">94.6%</span> for <span class="teal">8q12</span>, <span class="blue">92.9%</span> for <span class="blue">8q16</span>, <span class="gray">92.3%</span> for <span class="gray">2q8</span>.
                    </li>
                    <li>
                      83% of 8 mg patients maintained dosing intervals of &ge;12 weeks.
                    </li>
                    <li>
                      Mean number of injections were <span class="teal">6.1</span> for <span class="teal">8q12</span>, <span class="blue">5.2</span> for <span class="blue">8q16</span>, and <span class="gray">6.9</span> for <span class="gray">2q8</span>. 
                    </li>
                  </ul>

                  <p style="margin-left: 10px; font-size: 20px; font-weight: bold;">
                    Week 60<sup>2</sup>
                  </p>
                  <ul class="bullet-collapse">
                    <li>
                      87% of 8 mg patients maintained dosing intervals of &ge;12 weeks.
                    </li>
                    <li>
                      Mean number of injections were <span class="teal">7.1</span> for <span class="teal">8q12</span>, <span class="blue">6.2</span> for <span class="blue">8q16</span>, and <span class="gray">8.8</span> for <span class="gray">2q8</span>. 
                    </li>
                  </ul>

                  <p style="margin-left: 10px; font-size: 20px; font-weight: bold;">
                    Week 96<sup>2</sup>
                  </p>
                  <ul class="bullet-collapse">
                    <li>
                      88% of 8 mg patients maintained dosing intervals of &ge;12 weeks.
                    </li>
                    <li>
                      Mean number of injections were <span class="teal">9.7</span> for <span class="teal">8q12</span>, <span class="blue">8.2</span> for <span class="blue">8q16</span>, and <span class="gray">12.8</span> for <span class="gray">2q8</span>. 
                    </li>
                  </ul>
                </div>
              </div>
            </div>
                
            <div class="accordion-item">
              <h2 class="accordion-header" id="patients">
                <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#collapse-4">
                  Visual Outcomes
                </button>
              </h2>
              <div id="collapse-4" class="accordion-collapse collapse">
                <div class="accordion-body">
                  <ul class="bullet-collapse">
                    <li>
                      The 8q12 and 8q16 groups had non-inferior BCVA change compared to 2q8 through Weeks 48 and 96.<sup>1,2</sup> 
                    </li>
                  </ul>
                  <h2>
                    BCVA Outcomes (FAS)<sup style="top: -0em">2</sup>
                  </h2>
                  <div class="figure-white">
                    <img src="assets/img/BCVA-PULSAR.png" 
                        class="img-fluid">
                  </div>
                </div>
              </div>
            </div>
  
            <div class="accordion-item">
              <h2 class="accordion-header" id="results">
                <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#collapse-5">
                  Anatomic Outcomes
                </button>
              </h2>

              <div id="collapse-5" class="accordion-collapse collapse">
                <div class="accordion-body">
                  <h2>
                    Key Secondary Endpoint Results Through Week 48 (FAS)<sup style="top: -0em">1</sup>
                  </h2>

                  <div class="figure-white">
                    <img src="assets/img/secondary_outcomes.PNG" 
                      class="img-fluid">
                  </div>
                  <br><br>

                  <h2>
                    Absolute CST Through Week 96 (FAS)<sup style="top: -0em">2</sup>
                  </h2>
                  <div class="figure-white">
                    <img src="assets/img/CST.PNG"
                      class="img-fluid">
                  </div>
                  <ul class="bullet-collapse">
                    <li>
                      Change in CST was similar in all 3 treatment arms through 96 weeks, with minimal fluctuations over the course of treatment.<sup>2</sup>
                    </li>
                  </ul>
                </div>
              </div>
            </div>
          </div><br>
        </div>
      </div>
      
      <div id="safety" class="tab-pane" role="tabpanel">
        <div class="container-fluid">
          <h1>
            Safety
          </h1>
          <ul class="bullet">
            <li>
              The safety profile of IVT-AFL 8 mg was found to be similar to that of IVT-AFL 2 mg through 96 weeks.<sup>1-3</sup>
            </li>
            <li>
              Through Week 60:<sup>2</sup>
              <ul>
                <li>
                  Ocular TEAEs occurring in &ge;3% of patients in any treatment group were cataract, increased IOP (defined by preferred terms "intraocular pressure increased" and "ocular hypertension"), SRF, retinal hemorrhage, visual acuity reduced, and vitreous floaters. 
                </li>
              </ul>
            </li>
          </ul>
          
          <div class="container-collapse">
            <a class="btn btn-collapse" data-bs-toggle="collapse" aria-expanded="false" aria-controls="collapse-6" href="#collapse-6" role="button">Click to Expand/Collapse <br> Most Frequent TEAEs Through Week 60
            </a>
          </div>
  
            <div id="collapse-6" class="collapse">
              <h2>
                Most Frequent TEAEs through Week 60 (SAF)<sup style="top: -0em">2</sup>
              </h2>
              <div class="figure zoom">
                <img src="assets/img/safety.PNG" 
                class="img-fluid">
            </div>
          </div>
          <br>

          <ul class="bullet">
            <li>
              Through Week 96:<sup>3</sup>
              <ul>
                <li>
                  There were no cases of retinal vasculitis, occlusive retinitis, or endophthalmitis in the 8 mg group.
                </li>
                <li>
                  The rate of IOI was 1.3% for the 8 mg groups and 2.1% for the 2 mg group.
                </li>
                <li>
                  There was no difference in IOP increase rates between 8 mg and 2 mg.
                </li>
              </ul>
            </li>
          </ul>
        </div>
      </div>
  
      <div id="reference" class="tab-pane" role="tabpanel">
        <div class="container-fluid">
          <h1>
            References
          </h1>
          <ol style="margin-left: 30px; margin-right: 30px; margin-top: -20px; padding-right: 30px; padding-left: 30px; padding-bottom: 10px; padding-top: 10px; font-size: 20px;background-color: #f7f7f7;">
            <li>
              Korobelnik JF. Intravitreal aflibercept 8 mg injection in patients with neovascular age-related macular degeneration: 48-week results from the Phase 3 PULSAR Trial. Presented at: 55th Annual Scientific Meeting of The Retina Society; November 2-5 2022; Pasadena, CA. 
              <br><a href="https://investor.regeneron.com/static-files/d2cb2519-182f-42a6-8ac4-04544883febc" target="_blank">Link</a>
            </li>
            <li>
              Lanzetta P, et al. Intravitreal Aflibercept 8 mg Injection in Patients With Neovascular Age-Related Macular Degeneration: 60-Week and 96-Week Results from the Phase 3 PULSAR Trial. Presented at: EURETINA; October 5-8 2023; Amsterdam, The Netherlands.
              <br><a href="https://investor.regeneron.com/static-files/06016223-ff10-4fff-b9bb-3162f0ef27d9" target="_blank">Link</a>
            </li>
            <li>
              Bayer Press Release. Two-year topline results from the pivotal study PULSAR. August 10, 2023.
              <br><a href="https://www.bayer.com/media/en-us/aflibercept-8-mg-first-to-achieve-sustained-vision-gains-with-more-than-70-of-patients-extended-to-intervals-between-16-and-24-weeks-in-wet-age-related-macular-degeneration-at-two-years/" target="_blank">Link</a>
            </li>
          </ol>
        </div>
      </div><br><br>
    </div>
  
    <footer class="fixed-bottom">
      <div class="container-fluid">
        <button type="button" class="btn btn-abbrev" data-bs-toggle="popover" data-bs-container="body" data-bs-html="true" onclick="changeIcon(this)" title="Abbreviations" data-bs-content="
          <strong>2q8</strong> 2 mg every 8 weeks<br>
          <strong>8q12</strong> 8 mg every 12 weeks<br>
          <strong>8q16</strong> 8 mg every 16 weeks<br>
          <strong>AE</strong> adverse events<br>
          <strong>BCVA</strong> best-corrected visual acuity<br>
          <strong>BL</strong> baseline<br>
          <strong>CI</strong> confidence interval<br>
          <strong>CNV</strong> choroidal neovascularization<br>
          <strong>CRT</strong> central retinal thickness<br>
          <strong>CST</strong> subfield retinal thickness<br>
          <strong>DRM</strong> dose regimen modification<br>
          <strong>ETDRS</strong> Early Treatment Diabetic Retinopathy Study<br>
          <strong>FAS</strong> full analysis set<br>
          <strong>IOI</strong> intraocular inflammation<br>
          <strong>IOP</strong> intraocular pressure<br>
          <strong>IRF</strong> intraretinal fluid<br>
          <strong>IVT-AFL</strong> intravitreal aflibercept<br>
          <strong>LS</strong> least squares<br>
          <strong>n</strong> number<br>
          <strong>NA</strong> not applicable<br>
          <strong>nAMD</strong> neovascular age-related macular degeneration<br>
          <strong>pts</strong> patients<br>
          <strong>q8</strong> every 8 weeks<br>
          <strong>q12</strong> every 12 weeks<br>
          <strong>q20</strong> every 20 weeks<br>
          <strong>q24</strong> every 24 weeks<br>
          <strong>SAF</strong> safety analysis set<br>
          <strong>SRF</strong> subretinal fluid<br>
          <strong>TEAE</strong> treatment emergent adverse event<br>">
        <i id ="fa" class="fas fa-list"></i>
        </button>
  
    <button type="button" class="btn btn-ref" data-bs-toggle="popover" data-bs-container="body" data-bs-html="true" title="References" onclick="changeIcon(this)" data-bs-content="
      <ol>
        <li>
          Korobelnik JF. Intravitreal aflibercept 8 mg injection in patients with neovascular age-related macular degeneration: 48-week results from the Phase 3 PULSAR Trial. Presented at: 55th Annual Scientific Meeting of The Retina Society; November 2-5 2022; Pasadena, CA. 
          <br><a href='https://investor.regeneron.com/static-files/d2cb2519-182f-42a6-8ac4-04544883febc' target='_blank'>Link</a>
        </li>
        <li>
          Lanzetta P, et al. Intravitreal Aflibercept 8 mg Injection in Patients With
          Neovascular Age-Related Macular Degeneration:
          60-Week and 96-Week Results from the Phase 3 PULSAR Trial. Presented at: EURETINA; October 5-8 2023; Amsterdam, The Netherlands.
          <br><a href='https://investor.regeneron.com/static-files/06016223-ff10-4fff-b9bb-3162f0ef27d9' target='_blank'>Link</a>
        </li>
        <li>
          Bayer Press Release. Two-year topline results from the pivotal study PULSAR. August 10, 2023.
          <br><a href='https://www.bayer.com/media/en-us/aflibercept-8-mg-first-to-achieve-sustained-vision-gains-with-more-than-70-of-patients-extended-to-intervals-between-16-and-24-weeks-in-wet-age-related-macular-degeneration-at-two-years/' target='_blank'>Link</a>
        </li>
     </ol>">
     <i id="fa" class="fas fa-scroll"></i>
    </button>
      </div>
      <a href="#" id="scroll" style="display: none;"><span></span></a>
    </footer>   
  </div>
</div>

<script>  
  var popoverTriggerList = [].slice.call(document.querySelectorAll('[data-bs-toggle="popover"]'))
  var popoverList = popoverTriggerList.map(function (popoverTriggerEl) 
  {
    return new bootstrap.Popover(popoverTriggerEl)
  });
</script>
</body>

</html>